Fwiw, SRCL appears to be putting in a bottom, and has formed a quasi inverted head + shoulders. What happens next will depend on upcoming earnings and company guidance, and might take a couple quarters of improvement to really get a turnaround going. But the need for medical waste disposal will only increase over time, and SRCL is the biggest player, so this looks like a good long term contrarian value stock imo.
TEVA is another great stock that has fallen out of favor, cut in half since mid 2015. The company has a lot more debt now after doing a big acquisition, and revenues from their big MS drug Copaxone will be way down, but much of this is already reflected in the demolished stock price. The CEO is being replaced and there's a good chance the dividend will be cut, so a turnaround will take time. But for patient investors this looks like a tempting contrarian value play. TEVA will remain the 800 lb gorilla in the generic drug sector.
News 
Market Data 
Discover 
